10-Q: Cabaletta Bio Reports First Quarter 2025 Financial Results and Provides Business Update

Cabaletta Bio reports its financial results for the first quarter of 2025, highlighting progress in its clinical programs and strategic initiatives.

Summary

• Cabaletta Bio, a clinical-stage biotechnology company, announced its financial results for the first quarter ended March 31, 2025.
• The company is focused on developing engineered T cell therapies for autoimmune diseases.
• Cabaletta's lead product candidate, rese-cel, is undergoing Phase 1/2 clinical trials for SLE, myositis, SSc, gMG, PV and MS.
• The company reported a net loss of $35.9 million for the quarter, compared to a net loss of $25.0 million for the same period in 2024.
• Research and development expenses increased to $29.0 million from $22.0 million year-over-year, driven by clinical trial and personnel costs.
• General and administrative expenses were $8.1 million, up from $6.1 million in the prior year, primarily due to increased personnel costs.
• As of March 31, 2025, Cabaletta had $131.8 million in cash and cash equivalents, expected to fund operations into the first half of 2026.
• The company is pursuing multiple strategies for commercial, scalable manufacturing capabilities, including CDMO relationships and potentially its own facilities.
• Cabaletta is working with active clinical sites to incorporate the RESET-PV TM trial as a sub-study within the Phase 1 DesCAARTes TM trial following the submission of a protocol amendment.
• In late June 2024, a lupus nephritis patient with very active, refractory disease was dosed with rese-cel and experienced Grade 1 CRS and a protocol-defined dose-limiting toxicity of Grade 4 ICANS.
• In January 2025, the FDA granted clearance of our rese-cel IND application for treatment of multiple sclerosis, or MS.
• In February 2025, Cabaletta announced updated clinical and translational data from the first 10 patients in the RESET TM clinical trial program, with a data cut off of January 8, 2025.
• In March 2025, Cabaletta learned of an important protocol deviation in the RESET-SSc TM trial.
• Following a Type C meeting with the FDA and receipt of meeting minutes in April 2025, Cabaletta is planning to implement the following design for two single-arm, disease-specific registrational cohorts in the ongoing RESET-Myositis TM trial.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive developments in clinical trials and regulatory designations, the increased net loss and potential risks associated with product development and commercialization temper the overall outlook.

Positives

• The FDA granted clearance of the rese-cel IND application for treatment of multiple sclerosis.
• The FDA granted Fast Track Designation for rese-cel for the treatment of relapsing and progressive forms of MS.
• Cabaletta is working with active clinical sites to incorporate the RESET-PV TM trial as a sub-study within the Phase 1 DesCAARTes TM trial following the submission of a protocol amendment.
• Following a Type C meeting with the FDA and receipt of meeting minutes in April 2025, Cabaletta is planning to implement the following design for two single-arm, disease-specific registrational cohorts in the ongoing RESET-Myositis TM trial.

Negatives

• Cabaletta Bio reported a net loss of $35.9 million for Q1 2025, compared to $25.0 million in Q1 2024.
• In late June 2024, a lupus nephritis patient with very active, refractory disease was dosed with rese-cel and experienced Grade 1 CRS and a protocol-defined dose-limiting toxicity of Grade 4 ICANS.
• In March 2025, Cabaletta learned of an important protocol deviation in the RESET-SSc TM trial.

Risks

• The company has incurred net losses in every period since its inception and anticipates that it will incur substantial net losses over the next several years, and may never achieve or maintain profitability.
• The company has identified conditions that raise substantial doubt about its ability to continue as a going concern.
• The company is reliant on Penn and Minaris Advanced Therapies for its current manufacturing activities and Penn and/or Minaris Advanced Therapies' failure to perform or termination would disrupt normal business operations.
• The company is reliant on intellectual property licensed to it by Penn and Nanjing IASO Biotherapeutics Co., Ltd., or IASO, and termination of one of these license agreements would result in the loss of significant rights, which would have a material adverse effect on our business.
• The company may encounter substantial delays in its clinical trials or may not be able to conduct its trials on the timelines it expects or at all.
• The company may face significant competition from other biotechnology and pharmaceutical companies, and its operating results will suffer if it fails to compete effectively.
• The company's product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.

Future Outlook

The company expects its current cash and cash equivalents to be sufficient to fund operations into the first half of 2026 and plans to continue developing its product candidates and exploring strategic collaborations.

Industry Context

Cabaletta Bio is operating in the rapidly evolving field of engineered T cell therapies for autoimmune diseases, competing with other biotechnology and pharmaceutical companies, academic research organizations, and governmental agencies.

Comparison to Industry Standards

• The company is developing novel CAR T and CAAR T cell product candidates that are unique biological entities, the regulatory requirements that we will be subject to are not entirely clear.
• Even with respect to more established products that fit into the categories of gene therapies or cell therapies, the regulatory landscape is still developing.
• For example, regulatory requirements governing gene therapy products and cell therapy products have changed frequently and may continue to change in the future.
• Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing gene therapy products and cell therapy products.
• In the United States, the FDA established the Office of Tissues and Advanced Therapies, or OTAT, in 2016, within its Center for Biologics Evaluation and Research, or CBER, to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review.
• In September 2022, the FDA announced retitling of OTAT to the Office of Therapeutic Products, or OTP, and elevation of OTP to a Super Office to meet its growing cell and gene therapy workload.
• In the European Union, a special committee called the Committee for Advanced Therapies was established within the EMA in accordance with Regulation (EC) No 1394/2007 on advanced-therapy medicinal products, or ATMPs, to assess the quality, safety and efficacy of ATMPs, and to follow scientific developments in the field.
• ATMPs include gene therapy products as well as somatic cell therapy products and tissue engineered products.

Stakeholder Impact

• Shareholders: Dilution from potential future equity offerings.
• Patients: Potential for new treatment options for autoimmune diseases.
• Employees: Job security dependent on successful product development and funding.
• Suppliers: Continued business relationships for manufacturing and clinical trial support.

Next Steps

• Continue clinical trials for rese-cel in SLE, myositis, SSc, gMG, PV and MS.
• Pursue strategies for commercial, scalable manufacturing capabilities.
• Present new clinical data from RESET-Myositis TM , RESET-SLE TM and RESET-SSc TM trials at the EULAR 2025 Congress.
• Implement design for two single-arm, disease-specific registrational cohorts in the ongoing RESET-Myositis TM trial.

Key Dates

Keywords

rese-cel, Cabaletta Bio, autoimmune diseases, T cell therapies, clinical trials, financial results, regulatory approval, manufacturing, CD19, IASO, Minaris Advanced Therapies, Oxford Biomedica, RESET TM, MusCAARTes TM, SLE, myositis, SSc, gMG, PV, MS